PRAJAKTA G KALE

Reference:Dr.RATHI JAYPRAKASH MD(ME

SID: 120554052

120554052

Collection Date:
30-03-2021 10:02 AM

Sample Date:
30-03-2021 10:02 am

Report Date:
30-03-2021 05:01 pm

REPORT

Tel No: 919823027643
PID: 11136697

Age:59.10 Years Sex:FEMALE

Complete Blood Count	Result	Biological Reference Interval
(EDTA Whole Blood)		
Hemoglobin (Hb), EDTA whole blood	**13.50**	12.3 - 15.3 g/dL
Method: Photometry		
Total Leucocytes (WBC) count	**6,900**	4000-10000/µL
Method : Coulter Principle / Microscopy		
Platelet count	**377,000**	150000 - 450000 /µL
Method : Coulter Principle / Microscopy		
Red blood cell (RBC) count	**4.92**	4.10 - 5.10 x 10^6 /µL
Method: Coulter Principle		
PCV (Packed Cell Volume)	**40.00**	35.9 - 44.6 %
Method: Calculated		
MCV (Mean Corpuscular Volume)	**81.20**	80.0 - 96.0 fL
Method: Derived from RBC histogram		
MCH (Mean Corpuscular Hb)	**27.40**	27.5 - 33.2 pgms
Method: Calculated		
MCHC (Mean Corpuscular Hb Conc.)	**33.80**	33.4 - 35.5 g/dL
Method: Calculated		
RDW (RBC distribution width)	**13.80**	11.6 - 14.6 %
Method: Derived from RBC Histogram		
WBC Differential Count		
Method: VCSn / Microscopy / Calculated		
Neutrophils	**52**	40 - 80 %
Absolute Neutrophils	**3,588**	2000 - 7000 /µL
Eosinophils	**3**	1 - 6 %
Absolute Eosinophils	**207**	20 - 500 /µL
Basophils	**0**	0 - 2 %
Absolute Basophils	**0**	0 - 100 /µL
Lymphocytes	**39**	20 - 40 %
Absolute Lymphocytes	**2,691**	1000 - 3000 /µL
Monocytes	**6**	2 - 10 %
Absolute Monocytes	**414**	200 - 1000 /µL
-	**##$**	

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Complete Blood Count Findings

R.B.C. : **Normocytic, Normochromic**

W.B.C. : **No abnormality detected**

Platelets : **Adequate**

Remark : ON FOLLOW UP

.
.
.
.

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Desciption	Observed Value	Biological Reference Interval
Lipid Profile Maxi :		
Serum Appearance	**Clear**	
Cholesterol (Total), serum by Enzymatic method	**190**	Desirable : < 200 mg/dL Borderline high : 200 - 239 mg/dL High : >/= 240 mg/dL
Triglycerides, serum by Enzymatic method	**110**	Normal : < 150 mg/dL Borderline high : 150-199 mg/dL High : 200-499 mg/dL Very high : >/= 500 mg/dL
HDL Cholesterol, serum by Enzymatic method	**54**	Men : > 40 mg/dL Women : > 50 mg/dL
VLDL Cholestrol, serum by calculation	**22**	< 30 mg/dL
LDL Cholesterol, serum by calculation	**114**	Optimal : <100 mg/dL Near optimal/above optimal : 100-129 mg/dL Borderline high : 130-159 mg/dL High : 160-189 mg/dL Very high : >/= 190 mg/dL
Cholesterol(Total)/HDL Cholesterol Ratio	**3.52**	Males : Acceptable ratio </= 5.00 Females : Acceptable ratio </= 4.50
LDL Cholesterol/HDL Cholesterol Ratio	**2.11**	Males : Acceptable ratio </= 3.60 Females : Acceptable ratio </= 3.20
Apolipoprotein A1, serum by Nephelometry	**174**	125 to 215 mg/dL
Apolipoprotein B, serum by Nephelometry	**89**	Female : 55 to 125 mg/dL

Reference : ATP III, NCEP Guidelines and National Lipid Association (NLA) 2014 Recommendations

As per most international and national guidelines including Lipid Association of India 2016 :

1. Lipoprotein and lipid levels should be considered in conjunction with other atherosclerotic cardiovascular disease (ASCVD) risk determinants to assess treatment goals and strategies.
2. Non-fasting lipid levels can be used in screening and in general risk estimation.

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

Test Description	Observed	Biological Reference Interval
Liver Function Test :		
Bilirubin-Total, serum by Diazo method	**0.40**	0.10 - 1.20 mg/dL Neonates : Upto 15.0 mg/dL
Bilirubin-Conjugated, serum by Diazo method	**0.20**	Upto 0.5 mg/dL
Bilirubin-Unconjugated, serum by calculation	**0.20**	0.1 to 1.0 mg/dL
SGOT (AST), serum by Enzymatic method	**16**	>or= 14 years : 8 - 43 U/Lt
SGPT (ALT), serum by Enzymatic Method	**18**	7 to 45 U/Lt
Alkaline Phosphatase,serum by pNPP-kinetic	**87**	Adult Female : (Unit : U/Lt.). 15 - < 17 years : 50 - 117 > or =17 years: 35 - 104
Protein (total), serum by Biuret method	**7.00**	6.4 to 8.2 g/dL
Albumin, serum by Bromocresol purple method	**4.10**	3.4 to 5.0 g/dL
Globulin, serum by calculation	**2.90**	2.3 - 3.5 g/dL

--XX--

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	Reference:Dr.RATHI JAYPRAKASH MD(ME	SID: 120554052
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		120554052 Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
TEST NAME		
Glycated Hemoglobin (HbA1C), by HPLC	**6.00**	4.0 to 5.6 %

Interpretation :
HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.

For diagnosis of Diabetes Mellitus (>/= 18 yrs of age) :
5.7 % - 6.4 % : Increased risk for developing diabetes.
>/= 6.5 % : Diabetes

Therapeutic goals for glycemic control :
Adults : < 7%
Toddlers and Preschoolers : < 8.5% (but > 7.5 %)
School age (6-12 yrs) : < 8%
Adolescents and young adults (13 - 19 yrs) : < 7.5 %

Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.
Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.
Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA. In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.

The A1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Ref : ADA (Standards of Medical Care in Diabetes - 2017)

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
Haematology :		
Erythrocyte Sedimentation Rate, EDTA Whole Blood	**10**	Female under 50 Yrs : Upto 20mm/hr. Female 50 - 85 Yrs : Upto 30mm/hr. Female > 85 yrs : Upto 42mm/hr. Results corrected to 18 deg. celsius

Technique : Automated Westergren Method .
1. ESR is markedly elevated in monoclonal gammopathy such as multiple myeloma, in severe polyclonal hyperglobulinemia due to inflammatory disease, and in hyperfibrinogenemia. 2. Moderate elevations are common in active inflammatory disease such as rheumatoid arthritis, chronic infections, collagen disease and neoplastic disease
3. ESR has little diagnostic value in these disorders but can be useful in monitoring disease activity.
4. Useful in the diagnosis and in monitoring polymyalgia rheumatica and temporal arteritis.
5. Moderate increase is seen in pregnancy (beginning at the 10th to 12th week) and returns to normal about 1 month postpartum .
6. Red cells with an abnormal or irregular shape, such as sickle cells or spherocytes, hinder rouleaux formation and lower the ESR.

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

Test Description	Observed Value	Biological Reference Interval
Plasma Glucose :		
Plasma glucose fasting, by Hexokinase method	**115**	< 100 mg/dL 100 to 125 mg/dL : Impaired fasting glucose tolerance / Prediabetes >/= 126 mg/dL : Suggestive of diabetes mellitus (On more than one occasion) American Diabetes Association Guidelines 2020
Plasma glucose post prandial, by Hexokinase method	**147**	< 140 mg/dL 140 to 199 mg/dL : Impaired glucose tolerance / Prediabetes >/= 200 mg/dL : Suggestive of diabetes mellitus (On more than one occasion) American Diabetes Association Guidelines 2020
Clinical Chemistry		
Urea, serum by GLDH-urease	**18**	17 to 49 mg/dL
BUN-Blood Urea Nitrogen,serum by calculation	**8.41**	8 to 23 mg/dL
Creatinine, serum by Jaffe w/o deproteinization	**0.71**	0.6 to 1.2 mg/dL

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
Clinical Chemistry :		
Uric Acid, serum by Uricase method	**3.20**	Female : 2.60 to 6.00 mg/dL

** Uric acid is useful for 1. Diagnosis and follow up of renal failure. 2. Monitoring patients receiving cytotoxic drugs and a variety of other disorders, including gout, leukemia, psoriasis, starvation and other wasting conditions . * Increased uric acid is seen in following conditions :*
1. Increased purine synthesis 2. Inherited metabolic disorders 3. Excess dietary purine intake
4. Increased nucleic acid turnover 5. Malignancy, cytotoxic drugs 6. Decreased urinary excretion (due to CRF) 7. Increased renal reabsorption .
** Uric acid is decreased in : 1. Hepatocellular disease with reduced purine synthesis*
2. Defective renal reabsorption 3. Overtreatment of uricemia (allopurinol or cancer therpies like 6-mercaptopurine, etc).

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	**Observed Value**	**Biological Reference Interval**
Clinical Chemistry :		
Calcium, serum by OCPC method	**8.70**	Adult : 8.4 to 10.2 mg/dL

Method : Colorimetric (o-cresolpthalein substrate) .
1. Calcium is useful for diagnosis and monitoring of a wide range of disorders including diseases of bone, kidney, parathyroid gland, or gastrointestinal tract .
2. Calcium ions play an important role in blood clotting, bone mineralization, musculature contractility and CNS functioning. .
3. Hypocalcemia is due to the absence or impaired function of the parathyroid glands or impaired vitamin-D synthesis. Chronic renal failure is also frequently associated with hypocalcemia due to decreased vitamin-D synthesis as well as hyperphosphatemia and skeletal resistance to the action of parathyroid hormone (PTH).
4. Hypercalcemia is mainly due to primary hyperparathyroidism (pHPT), and bone metastasis of carcinoma of the breast, thyroid gland, or lung. Severe hypercalcemia may result in cardiac arrhythmia.

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	Reference:Dr.RATHI JAYPRAKASH MD(ME	SID: 120554052
REPORT	Tel No: 919823027643 PID: 11136697		120554052 Collection Date: 30-03-2021 10:02 AM Sample Date:
	Age:59.10 Years Sex:FEMALE		30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
Clinical Chemistry :		
Serology		
RA-Rheumatoid Arthritis, serum by Nephelometry	**Negative (<9.19)**	Negative : Below 15.90 IU/mL

Clinical Information :
1.The diagnosis of rheumatoid arthritis (RA) is established primarily on clinical criteria and seroloic findings.
2. Positive results indicate probability of RA .
3. The titre of RA factor correlates poorly with disease activity.
4. However, patients with high titres tend to have more severe disease.
5. Patients with various non rheumatoid diseases characterised by chronic inflammation (like SLE, polymyositis tuberculosis, viral hepatitis, infections mononucleosis and influenza) may have positive tests for RF.

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
Serology :		
Hormones		
Free T3, serum by CMIA	**2.95**	1.71 to 3.71 pg/mL
Free T4, serum by CMIA	**1.10**	0.71 to 1.85 ng/dL
TSH(Ultrasensitive), serum by CMIA	**1.75** On Thyronorm	For non pregnant female : 0.40 - 4.00 µIU/mL For pregnant female : 1st trimester : 0.1 - 2.5 µIU/mL 2nd trimester : 0.2 - 3.0 µIU/mL 3rd trimester : 0.3 - 3.0 µIU/mL Ref : American Thyroid Association guidelines 2017

MC-3143

"Laboratory is accredited as per ISO 15189:2012, Certificate Number MC-3143. Scope available on request / @ ww

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
TEST NAME		
Vitamin B12, serum by CMIA	**427.0**	187 - 883 pg/mL

Interpretation :

1. Vitamin B12 (cobalamin) is necessary for hematopoiesis and normal neuronal function.

2. Vitamin B12 is decreased in

Decreased Serum B12
Pregnancy
Contraceptive hormones
Malabsorption
Ethanol ingestion
Smoking
Strict vegan diet
Pernicious anemia

3. Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states. Active B12 (Holotranscobalamin) is low in Vitamin B12 deficiency.

4. Please correlate in case of patients taking vitamin B12 supplementation.

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
TEST NAME		
25 - OH Vitamin D, serum by CMIA	**32.20**	Severe deficiency : < 10 ng/mL Mild to moderate deficiency : 10 to 19 ng/mL Optimum levels : 20 to 50 ng/mL Increased risk of hypercalciuria: 51 to 80 ng/mL Toxicity possible : > 80 ng/mL Ref. : Mayo Medical Laboratories These reference ranges represent clinical decision values, based on the 2011 Institute of Medicine report

Interpretation :

Vitamin D is vital for strong bones. It also has important, emerging roles in immune function and cancer prevention.

Vitamin D compounds in the body are exogenously derived by dietary means; from plants as 25-hydroxyvitamin D2 (ergocalciferol or calciferol) or from animal products as 25-hydroxyvitamin D3 (cholecalciferol or calcidiol).

Vitamin D may also be endogenously derived by conversion of 7-dihydrocholesterol to 25-hydroxyvitamin D3 in the skin upon ultraviolet exposure.

The total 25-hydroxyvitamin D (25-OH-VitD) level (the sum of 25-OH-vitamin D2 and 25-OH-vitamin D3) is the appropriate indicator of vitamin D body stores.

Patients with renal failure can have very high 25-OH-VitD levels without any signs of toxicity, as renal conversion to the active hormone 1,25-OH-VitD is impaired or absent.

Kindly corelate clinically, with supplementation history & repeat with fresh sample if necessary.

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

PRAJAKTA G KALE | Reference:Dr.RATHI JAYPRAKASH MD(ME | SID: 120554052

120554052

Collection Date: 30-03-2021 10:02 AM

Sample Date: 30-03-2021 10:02 am

Report Date: 30-03-2021 05:01 pm

REPORT

Tel No: 919823027643

PID: 11136697

Age:59.10 Years Sex:FEMALE

Urine Routine Examination	Result	Biological Reference Interval
(Sample : Urine, Automated / Semiautomated)		
Physical		
Quantity Examined	**5.0**	ml
Method : Visual		
Appearance	**Clear**	-
Method : Visual / Automated		
Colour	**Pale yellow**	-
Method : Visual / Automated		
Chemical (Dipstick)		
pH	**7.0**	4.6 - 8.0
Method : Indicator Principle		
Protein	**Absent**	Absent
Method : Sulphosalycylic Acid/ pH Indicator		
Glucose	**Absent**	Absent
Method : GOD-POD / Benedict's		
Acetone	**Absent**	Absent
Method : Sodium Nitroprusside reaction		
Bile Pigments	**Absent**	Absent
Method : Diazo Reaction / Fouchet's test		
Urobilinogen	**Not significant**	Not Significant
Method : Modified Ehrlich / Watson Schwartz		
Microscopy / Flow cytometry		
R.B.Cs	**1-2**	0 - 2 per hpf
Pus cells	**2-3**	0 - 5 per hpf
Epithelial cells	**1-2**	0 - 5 per hpf
Casts	**Not Detected**	-
Crystals	**Not Detected**	-

-

<-->

MC-3143

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.

	PRAJAKTA G KALE	**Reference:Dr.RATHI JAYPRAKASH MD(ME**	**SID: 120554052**
REPORT	Tel No: 919823027643 PID: 11136697 Age:59.10 Years Sex:FEMALE		**120554052** Collection Date: 30-03-2021 10:02 AM Sample Date: 30-03-2021 10:02 am Report Date: 30-03-2021 05:01 pm

Test Description	Observed Value	Biological Reference Interval
CRP(hs) - C- Reactive Protein high sensitivity	**8.42**	See clinical information below . Method : Nephelometry / Immunoturbidimetry

Clinical Information :

1. C-reactive protein (CRP) is a biomarker of inflammation. Plasma CRP concentrations increase rapidly and dramatically (100-fold or more) in response to tissue injury or inflammation.

2. High-sensitivity CRP (hs-CRP) is more precise than standard CRP when measuring baseline (i.e. normal) concentrations and enables a measure of chronic inflammation. It is recommended for cardiovascular risk assessment. Atherosclerosis is an inflammatory disease and hs-CRP has been endorsed by multiple guidelines as a biomarker of atherosclerotic cardiovascular disease risk.

Low cardiovascular risk : < 2.0 mg/L
High cardiovascular risk : >/= 2.0 mg/L
Acute inflammation : > 10.0 mg/L

3. A single test for high-sensitivity CRP (hs-CRP) may not reflect an individual patient's basal hs-CRP level. Repeat measurement may be required to firmly establish an individual's basal hs-CRP concentration. The lowest of the measurements should be used as the predictive value.

Reference : Mayo Medical Laboratories

End of Report

Dr.(Mrs.) Awanti Golwilkar Mehendale
MBBS,MD(Path) Regn.No:2000/02/1052
A.G Diagnostics Pvt. Ltd.